Nkarta (NKTX) Total Non-Current Liabilities (2019 - 2026)
Nkarta's quarterly Total Non-Current Liabilities came in at $86.1 million in Q1 2026, down 6.1% year-on-year from $91.7 million in Q1 2025, and down 6.18% quarter-over-quarter from $91.8 million in Q4 2025.
Nkarta has reported Total Non-Current Liabilities for 7 years, with the latest figure at $86.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 6.1% year-over-year to $86.1 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (down 6.1% YoY), and the FY2025 full-year result was $91.8 million, down 1.44% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $86.1 million, down from $91.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $104.5 million in Q3 2022, with the low at $77.6 million in Q1 2022.
- Average Total Non-Current Liabilities over 4 years is $89.7 million, with a median of $90.6 million recorded in 2025.
- Year-over-year, Total Non-Current Liabilities surged 366.69% in 2022 and retreated 6.1% in 2026.
- Tracing NKTX's Total Non-Current Liabilities over 4 years: stood at $104.5 million in 2022, then declined by 10.9% to $93.1 million in 2024, then decreased by 1.44% to $91.8 million in 2025, then fell by 6.18% to $86.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $86.1 million (Q1 2026), $91.8 million (Q4 2025), and $89.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 86.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.13 Mn |
| Dec 31, 2025 | 91.80 Mn |
| Sep 30, 2025 | 89.25 Mn |
| Jun 30, 2025 | 90.56 Mn |
| Mar 31, 2025 | 91.72 Mn |
| Dec 31, 2024 | 93.14 Mn |
| Sep 30, 2022 | 104.53 Mn |
| Jun 30, 2022 | 82.59 Mn |
| Mar 31, 2022 | 77.58 Mn |
| Dec 31, 2021 | 22.92 Mn |
| Sep 30, 2021 | 22.40 Mn |
| Jun 30, 2021 | 20.66 Mn |
| Mar 31, 2021 | 19.63 Mn |
| Dec 31, 2020 | 16.35 Mn |
| Sep 30, 2020 | 17.22 Mn |
| Jun 30, 2020 | 67.57 Mn |
| Dec 31, 2019 | 13.95 Mn |